Mauricio Torrealba Alonso, MD
Gastroenterology · Minneapolis, MNNPI 1730594193
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Boston Scientific at 41.9% of the total. 2025 is the largest year on record at $1,642, more than ten times the $83 reported in 2020.
Across 70 payments — averaging $56.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$437
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$355
- E.r. Squibb & Sons, L.L.C.$122
- Gilead$96
- plus $102 from 4 others
What the payments were for
- Speaking & faculty fees$50013%
- Travel & lodging$1,39236%
- Food & beverage$2,02852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $1,642 |
| AbbVie | 27 | $1,166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $437 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $355 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Gilead | 1 | $96 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $31 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,920 in reported general payments places this provider in the 75th percentile of 365 gastroenterology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 26 | $551 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 25 | $508 |
| Omeprazole | 27 | $482 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Minneapolis
- Joshua SloanMinneapolis$175K
- Stuart AmateauMinneapolis$123K
- Justin HowardMinneapolis$50K
- Guru TrikudanathanMinneapolis$46K
- Byron VaughnMinneapolis$46K
- Martin FreemanMinneapolis$32K
- Sasan MosadeghiMinneapolis$14K
- Nabeel AzeemMinneapolis$12K
- David LeungMinneapolis$12K
- John LakeMinneapolis$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.